MedPath

Addition of 400 microgram misoprotol to routine management of third stage of labour in women at risk for bleeding after delivery.

Recruiting
Conditions
Pregant women with known High risk factors for post partum hemorrhage.
Registration Number
CTRI/2014/03/004491
Lead Sponsor
NRS MEDICAL COLLEGE KOLKATA
Brief Summary

The present study is a randomized double bind placebo controlled  trial evaluating the efficacy and safety of  400 microgram misoprostol in addition to routine mangement of third stage of labour with 10 units of intramuscular oxytocin in women with high risk factors for PPH following vaginal delivery.The primary outcome measures  are  the postpartum blood loss and incidence of PPH.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
Female
Target Recruitment
200
Inclusion Criteria
  • Women with one or more of the high risk factors as multiple pregnancy •polyhydramnios •prolonged labour •labor augmented by oxytocin.
  • •H/O PPH in previous pregnancy.
  • •Post caesarean section (for vaginal delivery) •Obese patient (BMJ >30) •Grand multipara •APH •Severe preeclampsia/eclampsia.
  • •Anaemia(hb<10gm%).
Exclusion Criteria
  • Any contraindications for the use of misoprostol and oxytocin such as known hypersensitivity, asthma, epilepsy etc.
  • Cardiovascular, hepatic, haematological disorders.
  • Temperature >38ï‚°C.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Blood loss after delivery and incidence of Post partum HaemorrhageFrom delivery of the newborn to 1 hour after delivery
Secondary Outcome Measures
NameTimeMethod
1.Post parum drop of Haemoglobin concentration2. need for additional oxytocic and blood transfusion

Trial Locations

Locations (1)

G&O OPD,ROOM NO-64. Kolkata WEST BENGAL

🇮🇳

Kolkata, WEST BENGAL, India

G&O OPD,ROOM NO-64. Kolkata WEST BENGAL
🇮🇳Kolkata, WEST BENGAL, India
Dr Arindam Majumdar
Principal investigator
9231509828
arindamsutia@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.